You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameKetobemidone
Accession NumberDB06738
TypeSmall Molecule
GroupsApproved
DescriptionKetobemidone is a powerful opioid analgesic. Its effectiveness against pain is in the same range as morphine, and it also has some NMDA-antagonist properties. This makes it useful for some types of pain that don't respond well to other opioids. The most commonly cited equalisation ratio for analgesic doses is 25 mg of ketobemidone hydrobromide to 60 mg of morphine hydrochloride or sulfate and circa 8 mg of ketobemidone by injection.
Structure
Thumb
Synonyms
Cetobemidona
Cetobemidone
Cetobemidonum
Cliradon
Cymidon
Ketobemidone
Ketodur
Ketogan
Ketorax
External Identifiers
  • UNII-PQS1L514CF
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CliradonPfizer
KetoganPfizer
KetoraxPfizer
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Ketobemidone hydrochloride
Thumb
  • InChI Key: ALFGKMXHOUSVAD-UHFFFAOYSA-N
  • Monoisotopic Mass: 247.157228921
  • Average Mass: 247.3327
DBSALT000189
Categories
UNIIPQS1L514CF
CAS number469-79-4
WeightAverage: 247.3327
Monoisotopic: 247.157228921
Chemical FormulaC15H21NO2
InChI KeyALFGKMXHOUSVAD-UHFFFAOYSA-N
InChI
InChI=1S/C15H21NO2/c1-3-14(18)15(7-9-16(2)10-8-15)12-5-4-6-13(17)11-12/h4-6,11,17H,3,7-10H2,1-2H3
IUPAC Name
1-[4-(3-hydroxyphenyl)-1-methylpiperidin-4-yl]propan-1-one
SMILES
CCC(=O)C1(CCN(C)CC1)C1=CC(O)=CC=C1
Pharmacology
IndicationFor the treatment of all types of severe pain, such as postoperative, cancer, kidney stones and fractures.
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionKetobemidone (Cliradon, Ketogan, Ketodur, Cymidon, Ketorax, &c.) is a powerful opioid analgesic. Its effectiveness against pain is in the same range as morphine, and it also has some NMDA-antagonist properties. This makes it useful for some types of pain that don't respond well to other opioids. The most commonly cited equalisation ratio for analgesic doses is 25 mg of ketobemidone hydrobromide to 60 mg of morphine hydrochloride or sulfate and circa 8 mg of ketobemidone by injection.
TargetKindPharmacological actionActionsOrganismUniProt ID
Mu-type opioid receptorProteinyes
agonist
HumanP35372 details
Kappa-type opioid receptorProteinyes
agonist
HumanP41145 details
Delta-type opioid receptorProteinyes
agonist
HumanP41143 details
NMDA receptorProtein groupunknown
antagonist
Humannot applicabledetails
Related Articles
Absorption34% (oral), 44% (rectal)
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Ketobemidone is mainly metabolised by conjugation of the phenolic hydroxyl group, and by N-desmethylation. Only about 13-24% is excreted unchanged after iv. administration.

SubstrateEnzymesProduct
Ketobemidone
Reduced ketobemidoneDetails
Ketobemidone
NorketobemidoneDetails
Ketobemidone
Ketobemidone N-oxideDetails
Norketobemidone
Not Available
Dihydroxy norketobemidoneDetails
Ketobemidone
Dihydroxy ketobemidoneDetails
Dihydroxy ketobemidone
Not Available
p-Hydroxymethoxy ketobemidoneDetails
Dihydroxy ketobemidone
Not Available
m-Hydroxymethoxy ketobemidoneDetails
Route of eliminationNot Available
Half lifePlasma half-life: 2.42 +/- 0.41 h (m +/- SD). Elimination half-life: 3.27 +/- 0.32 h
ClearanceNot Available
ToxicityBase: Rat Intravenous LD50: 10 mg/kg; Mouse Intravenous LD50: 14 mg/kg. Hydrochloride salt: Rat Oral LD50: 215 mg/kg; Rat Intravenous LD50: 40 mg/kg
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Ketobemidone Action PathwayDrug actionSMP00690
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Ketobemidone.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Ketobemidone.Experimental, Illicit
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Ketobemidone.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Ketobemidone.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Ketobemidone.Experimental
AbirateroneThe serum concentration of Ketobemidone can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Ketobemidone.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Ketobemidone.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Acetazolamide.Approved, Vet Approved
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Ketobemidone.Approved
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Ketobemidone.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Ketobemidone.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Ketobemidone.Approved, Illicit
AlimemazineAlimemazine may increase the hypotensive activities of Ketobemidone.Approved, Vet Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Ketobemidone.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ketobemidone.Approved, Illicit, Investigational
AlvimopanThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Alvimopan.Approved
AmilorideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Amiloride.Approved
AmiodaroneThe metabolism of Ketobemidone can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Ketobemidone.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Amitriptyline.Approved
Ammonium chlorideAmmonium chloride may increase the excretion rate of Ketobemidone which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ketobemidone.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Amperozide.Experimental
AmphetamineAmphetamine may increase the analgesic activities of Ketobemidone.Approved, Illicit
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Ketobemidone.Approved
AprepitantThe serum concentration of Ketobemidone can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ketobemidone.Approved, Investigational
ArmodafinilThe metabolism of Ketobemidone can be decreased when combined with Armodafinil.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Ketobemidone.Approved
AtazanavirThe metabolism of Ketobemidone can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Ketobemidone can be decreased when combined with Atomoxetine.Approved
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Ketobemidone.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Ketobemidone.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Azaperone.Vet Approved
AzelastineKetobemidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Azelastine.Approved
AzosemideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Azosemide.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Ketobemidone.Illicit
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Ketobemidone.Withdrawn
BendroflumethiazideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Bendroflumethiazide.Approved
BenperidolThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Benperidol.Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Ketobemidone.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Ketobemidone.Approved
BenzphetamineBenzphetamine may increase the analgesic activities of Ketobemidone.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Benzyl alcohol.Approved
BexaroteneThe serum concentration of Ketobemidone can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Ketobemidone.Approved
BL-1020BL-1020 may increase the hypotensive activities of Ketobemidone.Investigational
BoceprevirThe metabolism of Ketobemidone can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Ketobemidone can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Ketobemidone can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ketobemidone.Approved, Illicit
BrompheniramineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Brotizolam.Approved, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ketobemidone.Approved, Investigational
BuprenorphineKetobemidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Ketobemidone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ketobemidone.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Ketobemidone.Approved, Illicit
ButorphanolButorphanol may decrease the analgesic activities of Ketobemidone.Approved, Illicit, Vet Approved
Canrenoic acidThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Canrenoic acid.Approved, Withdrawn
CanrenoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Canrenone.Investigational
CapecitabineThe metabolism of Ketobemidone can be decreased when combined with Capecitabine.Approved, Investigational
CarbamazepineThe metabolism of Ketobemidone can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Ketobemidone.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Carisoprodol.Approved
CelecoxibThe metabolism of Ketobemidone can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Ketobemidone can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Ketobemidone.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Ketobemidone can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ketobemidone.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Ketobemidone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ketobemidone.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Chlorphenamine.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Ketobemidone.Withdrawn
ChlorphentermineChlorphentermine may increase the analgesic activities of Ketobemidone.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ketobemidone.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ketobemidone.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Ketobemidone can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CicletanineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Cicletanine.Investigational
CimetidineThe metabolism of Ketobemidone can be decreased when combined with Cimetidine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ketobemidone.Approved, Vet Approved
CitalopramThe metabolism of Ketobemidone can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Ketobemidone can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Ketobemidone can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Ketobemidone.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Clonidine.Approved
ClopidogrelThe metabolism of Ketobemidone can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ketobemidone.Approved, Illicit
ClotrimazoleThe metabolism of Ketobemidone can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Ketobemidone.Approved
CobicistatThe metabolism of Ketobemidone can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Ketobemidone.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Ketobemidone.Approved, Illicit
ConivaptanThe serum concentration of Ketobemidone can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Ketobemidone can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ketobemidone.Approved
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Ketobemidone.Approved
CyclosporineThe metabolism of Ketobemidone can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Cyclothiazide.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Ketobemidone can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ketobemidone.Approved
DapoxetineKetobemidone may increase the serotonergic activities of Dapoxetine.Investigational
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Ketobemidone.Approved, Investigational
DarunavirThe metabolism of Ketobemidone can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Ketobemidone can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Ketobemidone can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Ketobemidone can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Ketobemidone.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Ketobemidone.Approved
DesipramineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Desmopressin.Approved
DesvenlafaxineKetobemidone may increase the serotonergic activities of Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Ketobemidone can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Dexbrompheniramine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Ketobemidone.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ketobemidone.Approved, Vet Approved
DextroamphetamineDextroamphetamine may increase the analgesic activities of Ketobemidone.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Ketobemidone.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ketobemidone.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Ketobemidone.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Ketobemidone.Approved, Illicit, Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Ketobemidone.Approved
DiethylpropionDiethylpropion may increase the analgesic activities of Ketobemidone.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ketobemidone.Approved, Illicit
DihydroergotamineThe metabolism of Ketobemidone can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ketobemidone.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ketobemidone.Experimental, Illicit
DiltiazemThe metabolism of Ketobemidone can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ketobemidone.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ketobemidone.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Doxepin.Approved
DoxorubicinThe metabolism of Ketobemidone can be decreased when combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Ketobemidone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Ketobemidone is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone.Approved, Illicit
DronedaroneThe metabolism of Ketobemidone can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone.Approved, Vet Approved
DrospirenoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Ketobemidone.Experimental, Illicit
DuloxetineKetobemidone may increase the serotonergic activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ketobemidone.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Ketobemidone.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Ketobemidone.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Ketobemidone can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Efonidipine.Approved
EluxadolineKetobemidone may increase the constipating activities of Eluxadoline.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Ketobemidone.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Ketobemidone can be decreased when it is combined with Enzalutamide.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Eplerenone.Approved
ErythromycinThe metabolism of Ketobemidone can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramKetobemidone may increase the serotonergic activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Ketobemidone can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Ketobemidone can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Ketobemidone.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ketobemidone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Etacrynic acid.Approved
EthanolKetobemidone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ketobemidone.Approved, Illicit, Withdrawn
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Ketobemidone.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Ethotoin.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Ethoxzolamide.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Ketobemidone.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Ketobemidone.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ketobemidone.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Ketobemidone.Approved
EtoperidoneKetobemidone may increase the serotonergic activities of Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Ketobemidone.Illicit, Vet Approved
EtravirineThe serum concentration of Ketobemidone can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Felbamate.Approved
FelodipineThe metabolism of Ketobemidone can be decreased when combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Ketobemidone.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ketobemidone.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Ketobemidone.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Flibanserin.Approved
FloxuridineThe metabolism of Ketobemidone can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Ketobemidone can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Ketobemidone.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Ketobemidone.Approved, Illicit
FluorouracilThe metabolism of Ketobemidone can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Ketobemidone can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ketobemidone.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ketobemidone.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ketobemidone.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Ketobemidone.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Fluticasone Propionate.Approved
FluvastatinThe metabolism of Ketobemidone can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Ketobemidone can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Ketobemidone can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Ketobemidone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Ketobemidone can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Ketobemidone.Approved, Illicit
FurosemideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Ketobemidone can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ketobemidone.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Ketobemidone is combined with gabapentin enacarbil.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Ketobemidone.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Ketobemidone.Approved, Illicit
GemfibrozilThe metabolism of Ketobemidone can be decreased when combined with Gemfibrozil.Approved
GepironeThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Ketobemidone.Approved, Illicit
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Ketobemidone.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Ketobemidone.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ketobemidone.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Ketobemidone.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Ketobemidone.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Ketobemidone.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ketobemidone.Approved
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Ketobemidone.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneKetobemidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ketobemidone.Approved, Illicit
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Ketobemidone.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Ketobemidone.Approved
IdelalisibThe serum concentration of Ketobemidone can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Iloperidone.Approved
ImatinibThe metabolism of Ketobemidone can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Imipramine.Approved
IndalpineKetobemidone may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Indapamide.Approved
IndinavirThe metabolism of Ketobemidone can be decreased when combined with Indinavir.Approved
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Ketobemidone.Approved
IrbesartanThe metabolism of Ketobemidone can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Ketobemidone can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Ketobemidone.Approved, Vet Approved
IsoniazidThe metabolism of Ketobemidone can be decreased when combined with Isoniazid.Approved
IsosorbideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Isosorbide.Approved
IsradipineThe metabolism of Ketobemidone can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Ketobemidone can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Ketobemidone can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Ketobemidone.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Ketobemidone can be decreased when combined with Ketoconazole.Approved, Investigational
KW-3902The risk or severity of adverse effects can be increased when Ketobemidone is combined with KW-3902.Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Lamotrigine.Approved, Investigational
LapatinibThe metabolism of Ketobemidone can be decreased when combined with Lapatinib.Approved, Investigational
LeflunomideThe metabolism of Ketobemidone can be decreased when combined with Leflunomide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Ketobemidone.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ketobemidone.Approved
LevomilnacipranKetobemidone may increase the serotonergic activities of Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ketobemidone.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Ketobemidone.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Ketobemidone.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Ketobemidone.Approved
LofentanilThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Lofentanil.Illicit
LopinavirThe metabolism of Ketobemidone can be decreased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ketobemidone.Approved
LosartanThe metabolism of Ketobemidone can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Ketobemidone can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Ketobemidone.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Ketobemidone.Investigational
LuliconazoleThe serum concentration of Ketobemidone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Ketobemidone can be increased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Maprotiline.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Ketobemidone.Approved
MeclizineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Ketobemidone.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Melperone.Approved
MephedroneMephedrone may increase the analgesic activities of Ketobemidone.Investigational
MephentermineMephentermine may increase the analgesic activities of Ketobemidone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ketobemidone.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ketobemidone.Approved, Illicit
MersalylThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Mersalyl.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ketobemidone.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Ketobemidone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Ketobemidone.Approved, Illicit
MethamphetamineMethamphetamine may increase the analgesic activities of Ketobemidone.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Ketobemidone.Approved
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Ketobemidone.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Ketobemidone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Ketobemidone.Approved
MethotrimeprazineKetobemidone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ketobemidone.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Methyclothiazide.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Ketobemidone.Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ketobemidone.Approved
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Ketobemidone.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Metolazone.Approved
MetyrosineKetobemidone may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Ketobemidone.Approved, Illicit
MifepristoneThe serum concentration of Ketobemidone can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranKetobemidone may increase the serotonergic activities of Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone.Approved, Investigational
MirtazapineKetobemidone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Ketobemidone can be decreased when it is combined with Mitotane.Approved
MMDAMMDA may increase the analgesic activities of Ketobemidone.Experimental, Illicit
MoclobemideThe metabolism of Ketobemidone can be decreased when combined with Moclobemide.Approved
ModafinilThe serum concentration of Ketobemidone can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Ketobemidone.Approved
MoricizineMoricizine may increase the hypotensive activities of Ketobemidone.Approved, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Ketobemidone.Approved, Investigational
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Ketobemidone.Vet Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone.Approved, Investigational
NafcillinThe serum concentration of Ketobemidone can be decreased when it is combined with Nafcillin.Approved
NalbuphineNalbuphine may decrease the analgesic activities of Ketobemidone.Approved
NaltrexoneThe therapeutic efficacy of Ketobemidone can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NefazodoneThe metabolism of Ketobemidone can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Ketobemidone can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Ketobemidone can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Ketobemidone can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Ketobemidone can be decreased when combined with Nicardipine.Approved
NilotinibThe metabolism of Ketobemidone can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ketobemidone.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Ketobemidone.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Nortriptyline.Approved
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Ketobemidone.Investigational
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ketobemidone.Approved, Investigational
OlaparibThe metabolism of Ketobemidone can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Olopatadine.Approved
OmeprazoleThe metabolism of Ketobemidone can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ketobemidone.Approved
OpiumThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Opium.Approved, Illicit
OrphenadrineKetobemidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Ketobemidone.Investigational
OsimertinibThe serum concentration of Ketobemidone can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ketobemidone.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Ketobemidone.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Ketobemidone.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Ketobemidone.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ketobemidone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ketobemidone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Ketobemidone.Approved
PalbociclibThe serum concentration of Ketobemidone can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ketobemidone.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Ketobemidone.Approved
PantoprazoleThe metabolism of Ketobemidone can be decreased when combined with Pantoprazole.Approved
ParaldehydeKetobemidone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe metabolism of Ketobemidone can be decreased when combined with Paroxetine.Approved, Investigational
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Ketobemidone.Approved
PentazocinePentazocine may decrease the analgesic activities of Ketobemidone.Approved, Vet Approved
PentobarbitalThe metabolism of Ketobemidone can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Ketobemidone.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone.Approved
PerazineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ketobemidone.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ketobemidone.Approved
PhenobarbitalThe metabolism of Ketobemidone can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Phenoxyethanol.Approved
PhenterminePhentermine may increase the analgesic activities of Ketobemidone.Approved, Illicit
PhenytoinThe metabolism of Ketobemidone can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Ketobemidone.Approved
PioglitazoneThe metabolism of Ketobemidone can be decreased when combined with Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Pipamperone.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Ketobemidone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Pipotiazine.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Ketobemidone.Approved
PiretanideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Piretanide.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Pizotifen.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Ketobemidone can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PotassiumThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Potassium.Approved
Potassium CitrateThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Potassium Citrate.Approved, Vet Approved
PramipexoleKetobemidone may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Ketobemidone.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ketobemidone.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Ketobemidone.Approved
PrimidoneThe metabolism of Ketobemidone can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Ketobemidone.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ketobemidone.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Ketobemidone.Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Ketobemidone.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Promethazine.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Ketobemidone.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ketobemidone.Approved, Vet Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Ketobemidone.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Ketobemidone.Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Ketobemidone.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Ketobemidone.Investigational
PseudoephedrinePseudoephedrine may increase the analgesic activities of Ketobemidone.Approved
PyrimethamineThe metabolism of Ketobemidone can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe serum concentration of Ketobemidone can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ketobemidone.Approved
QuinethazoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Quinethazone.Approved
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Ketobemidone.Approved
QuinineThe metabolism of Ketobemidone can be decreased when combined with Quinine.Approved
RabeprazoleThe metabolism of Ketobemidone can be decreased when combined with Rabeprazole.Approved, Investigational
RacloprideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Ramelteon.Approved, Investigational
RamosetronKetobemidone may increase the constipating activities of Ramosetron.Approved
RanolazineThe metabolism of Ketobemidone can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ketobemidone.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ketobemidone.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Ketobemidone.Approved
RifabutinThe metabolism of Ketobemidone can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Ketobemidone can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Ketobemidone can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Ketobemidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Ritanserin.Investigational
RitobegronRitobegron may increase the analgesic activities of Ketobemidone.Investigational
RitonavirThe metabolism of Ketobemidone can be decreased when combined with Ritonavir.Approved, Investigational
RolofyllineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Rolofylline.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Romifidine.Vet Approved
RopiniroleKetobemidone may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ketobemidone.Approved
RosiglitazoneThe metabolism of Ketobemidone can be decreased when combined with Rosiglitazone.Approved, Investigational
RotigotineKetobemidone may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Ketobemidone.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Ketobemidone.Experimental
Sage 547The risk or severity of adverse effects can be increased when Ketobemidone is combined with Sage 547.Investigational
SaquinavirThe metabolism of Ketobemidone can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Scopolamine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Ketobemidone.Approved
SecobarbitalThe metabolism of Ketobemidone can be increased when combined with Secobarbital.Approved, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Ketobemidone.Approved, Withdrawn
SertralineThe metabolism of Ketobemidone can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ketobemidone.Approved, Vet Approved
SildenafilThe metabolism of Ketobemidone can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Ketobemidone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Ketobemidone can be increased when it is combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Ketobemidone.Approved
SorafenibThe metabolism of Ketobemidone can be decreased when combined with Sorafenib.Approved, Investigational
SpironolactoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Ketobemidone can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Ketobemidone can be increased when it is combined with Stiripentol.Approved
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Ketobemidone.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ketobemidone.Approved, Investigational
SulfadiazineThe metabolism of Ketobemidone can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Ketobemidone can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Ketobemidone can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ketobemidone.Approved
SuvorexantKetobemidone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TamoxifenThe metabolism of Ketobemidone can be decreased when combined with Tamoxifen.Approved
TandospironeThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Tasimelteon.Approved
TelaprevirThe metabolism of Ketobemidone can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Ketobemidone can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Ketobemidone.Approved
TeriflunomideThe metabolism of Ketobemidone can be decreased when combined with Teriflunomide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Ketobemidone.Investigational
ThalidomideKetobemidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Theobromine.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ketobemidone.Approved, Vet Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Ketobemidone.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Ketobemidone.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ketobemidone.Approved
ThiotepaThe metabolism of Ketobemidone can be decreased when combined with Thiotepa.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ketobemidone.Approved
TiagabineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Tiapride.Investigational
TicagrelorThe metabolism of Ketobemidone can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Ketobemidone can be decreased when combined with Ticlopidine.Approved
TicrynafenThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Tiletamine.Vet Approved
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Ketobemidone.Approved
TizanidineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Ketobemidone can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Ketobemidone can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Tolcapone.Approved, Withdrawn
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Ketobemidone.Approved, Investigational
TolvaptanThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Ketobemidone.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Ketobemidone.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ketobemidone.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Ketobemidone.Approved, Investigational
TriamtereneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Ketobemidone.Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ketobemidone.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ketobemidone.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Ketobemidone.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Ketobemidone.Approved
TrimethoprimThe metabolism of Ketobemidone can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Triprolidine.Approved
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Ketobemidone.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Ketobemidone.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Ketobemidone.Approved
Uc1010The risk or severity of adverse effects can be increased when Ketobemidone is combined with Uc1010.Investigational
UlaritideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Ularitide.Investigational
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Ketobemidone.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Ketobemidone.Approved, Investigational
ValsartanThe metabolism of Ketobemidone can be decreased when combined with Valsartan.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Ketobemidone.Approved
VenlafaxineThe metabolism of Ketobemidone can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Ketobemidone can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Vigabatrin.Approved
VoriconazoleThe metabolism of Ketobemidone can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Xylazine.Vet Approved
ZafirlukastThe metabolism of Ketobemidone can be decreased when combined with Zafirlukast.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ketobemidone.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Ziconotide.Approved
ZimelidineKetobemidone may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Ketobemidone can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Zolazepam.Vet Approved
ZolpidemKetobemidone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Ketobemidone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ketobemidone.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Bondesson U, Hartvig P, Danielsson B: Quantitative determination of the urinary excretion of ketobemidone and four of its metabolites after intravenous and oral administration in man. Drug Metab Dispos. 1981 Jul-Aug;9(4):376-80. [PubMed:6114838 ]
  2. Anderson P, Arner S, Bondesson U, Boreus LO, Hartvig P: Clinical pharmacokinetics of ketobemidone. Its bioavailability after rectal administration. Eur J Clin Pharmacol. 1981 Feb;19(3):217-23. [PubMed:7215421 ]
External Links
ATC CodesN02AG02N02AB01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (83.4 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.996
Blood Brain Barrier+0.9777
Caco-2 permeable+0.7753
P-glycoprotein substrateSubstrate0.8263
P-glycoprotein inhibitor INon-inhibitor0.6758
P-glycoprotein inhibitor IINon-inhibitor0.6722
Renal organic cation transporterInhibitor0.6578
CYP450 2C9 substrateNon-substrate0.8324
CYP450 2D6 substrateSubstrate0.6178
CYP450 3A4 substrateSubstrate0.6483
CYP450 1A2 substrateNon-inhibitor0.8062
CYP450 2C9 inhibitorNon-inhibitor0.889
CYP450 2D6 inhibitorInhibitor0.6678
CYP450 2C19 inhibitorNon-inhibitor0.9396
CYP450 3A4 inhibitorNon-inhibitor0.6532
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9154
Ames testNon AMES toxic0.882
CarcinogenicityNon-carcinogens0.8277
BiodegradationNot ready biodegradable0.9801
Rat acute toxicity2.5982 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6132
hERG inhibition (predictor II)Inhibitor0.6146
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point156.5 °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility3.01 mg/mLALOGPS
logP2.01ALOGPS
logP2.49ChemAxon
logS-1.9ALOGPS
pKa (Strongest Acidic)9.44ChemAxon
pKa (Strongest Basic)8.09ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area40.54 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity73.12 m3·mol-1ChemAxon
Polarizability28.09 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpiperidines. These are compounds containing a phenylpiperidine skeleton, which consists of a piperidine bound to a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPiperidines
Sub ClassPhenylpiperidines
Direct ParentPhenylpiperidines
Alternative Parents
Substituents
  • Phenylpiperidine
  • Aralkylamine
  • Phenol
  • Benzenoid
  • Gamma-aminoketone
  • Monocyclic benzene moiety
  • Tertiary aliphatic amine
  • Tertiary amine
  • Ketone
  • Azacycle
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Kristensen K, Christensen CB, Christrup LL, Nielsen LC: The mu1 and mu2 opioid receptor binding of ketobemidone, norketobemidone and 3-dimethylamino-1,1-diphenylbutene. Pharmacol Toxicol. 1996 Aug;79(2):103-4. [PubMed:8878254 ]
  2. Christensen CB: The opioid receptor binding profiles of ketobemidone and morphine. Pharmacol Toxicol. 1993 Dec;73(6):344-5. [PubMed:8153059 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:
OPRK1
Uniprot ID:
P41145
Molecular Weight:
42644.665 Da
References
  1. Christensen CB: The opioid receptor binding profiles of ketobemidone and morphine. Pharmacol Toxicol. 1993 Dec;73(6):344-5. [PubMed:8153059 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurot...
Gene Name:
OPRD1
Uniprot ID:
P41143
Molecular Weight:
40368.235 Da
References
  1. Christensen CB: The opioid receptor binding profiles of ketobemidone and morphine. Pharmacol Toxicol. 1993 Dec;73(6):344-5. [PubMed:8153059 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Voltage-gated cation channel activity
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. This protein plays a key role in synaptic plasticity, synaptogenesis, excitotoxicity, memory acquisition and learning. It mediates neuronal functions in glutamate neurotransmission. Is involved in the cell surface targeting of NMDA receptors (By similarity).
Components:
NameUniProt IDDetails
Glutamate receptor ionotropic, NMDA 1Q05586 Details
Glutamate receptor ionotropic, NMDA 2AQ12879 Details
Glutamate receptor ionotropic, NMDA 2BQ13224 Details
Glutamate receptor ionotropic, NMDA 2CQ14957 Details
Glutamate receptor ionotropic, NMDA 2DO15399 Details
Glutamate receptor ionotropic, NMDA 3AQ8TCU5 Details
Glutamate receptor ionotropic, NMDA 3BO60391 Details
References
  1. Ebert B, Andersen S, Krogsgaard-Larsen P: Ketobemidone, methadone and pethidine are non-competitive N-methyl-D-aspartate (NMDA) antagonists in the rat cortex and spinal cord. Neurosci Lett. 1995 Mar 10;187(3):165-8. [PubMed:7624018 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A9
Uniprot ID:
O60656
Molecular Weight:
59940.495 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on August 31, 2010 15:02 / Updated on August 17, 2016 12:24